Innate Immunotherapeutics (ATX AU): 2022 Is Going to Be a Watershed Year
The company is scheduled to start two phase 2 trials for its lead asset, with first results expected in mid-2023. Investors, with high-risk...
339 Views
S&P/ASX Indices: Quiddity Leaderboard for June 2022 Rebalance
A discussion on potential ADDs and DELETEs to the S&P ASX Indices between now and the completion of the June 2022 Regular Rebalance.
465 Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
5.8k Views
No more insights